Introduction
Hepatocellular carcinoma (HCC) is among the five most common cancer entities worldwide, with about half a million new cases diagnosed annually and an almost equal number of deaths, mostly due to early metastatic spread. About 15% of HCC patients only are candidates for surgical resection or liver transplantation. Standard chemotherapy is not applicable due to the intrinsically high chemoresistance of this tumour type. New strategies offering improvements in therapeutic efficacy and disease outcome are eagerly sought (1) (2) (3) .
Upregulation of growth and survival factors is an important hallmark of hepatocarcinogenesis and a major driving force for tumour progression and dissemination (1) (2) (3) (4) . We have recently found overexpression of fibroblast growth factor receptor 4 (FGFR4) in almost 50% of HCC cases investigated, which agrees with observations of another group (5, 6) . Also, FGFR4-ligands, such as FGF2 and FGF8-subfamily members, were found to be upregulated in many HCC cases investigated (5) (6) (7) (8) (9) (10) . FGFR4 belongs to a receptor tyrosine kinase (RTK) family of genes with similar protein structures (FGFR1-4) (7) (8) (9) (10) (11) . Upon ligand binding, the phosphorylated and dimerized form of FGFR4 recruits several adapter proteins, like FRS2α, and activates several signalling pathways including mitogen-activated protein kinase and phosphoinositide 3-kinase cascades. In dependence on the ligand, a great variety of cellbiological and biochemical processes may be affected, such as cell cycle regulation, survival, differentiation, migration, adhesion and/ or bile acid metabolism (8) (9) (10) (11) (12) . There is some evidence that FGFR4 may contribute to the development and progression of HCC, e.g. small interfering (siRNA) against FGF19 or antibodies targeting the FGF19-FGFR4 axis impaired the tumourigenicity of Huh7-cells, while this approach lacked significant effects in HepG 2 , SNU182 and SNU423 hepatoma/hepatocarcinoma cells (13) (14) (15) (16) .
Different FGFR ligands may impact in a specific way on one and the same receptor, as shown previously by the highly divergent molecular and biological effects of FGF7 and FGF10 on FGFR2b-mediated signalling (17) . Also FGF19 exerts unique features with regard to FGFR4-activation and metabolic effects in hepatocytes, which are not shared by other FGFR4-ligands (8, 11, 12) . We therefore used several hepatoma and recently established hepatocarcinoma cell lines which show inherent overexpression of FGF8-subfamily members, like 59% of the HCC cases studied (5, 18) . Because many FGFR4 ligands are upregulated in HCC, we targeted the receptor and applied not only siRNA and kinase-dead FGFR4-construct but also a soluble FGFR4-protein, which may be applicable in the near future, as exemplified by soluble decoy FGFR1c receptor being currently tested in a phase 1 clinical trial to treat solid tumours (19) . In addition, a novel, three-dimensional bulk invasion assay was used to analyse the mechanism of tumour cell-mediated disruption of blood or lymphatic vessels (20) . For the first time, we show that FGFR4 overexpression reduced cell adhesion and enhanced anchorage-independent growth and disintegration of the lymph/blood-endothelial barrier. The boosted aggressive phenotype was confirmed by accelerated tumour formation of the HCC cells in severe combined immunodeficiency (SCID) mice. In contrast, transfection with FGFR4-targeting siRNA or with kinase-deficient or soluble forms of FGFR4 impaired the malignant cell phenotype in vitro and tumour formation in vivo. Thus, use of soluble FGFR4-protein appeared as promising therapeutic option. In-depth investigations revealed that deregulations in FGFR4-mediated signalling affect genes involved in cell-matrix interactions, chromosome segregation and/or cytokinesis. These findings together provide mechanistic insight into the role of FGFR4 as one of the key drivers of the malignant phenotype of HCC cells.
Experimental procedures
Cells HepG 2 and CCl-13 were obtained from ATCC (Rockville, MD). HCC-1.2 and HCC-3 lines, and telomerase-immortalized human lymphendothelial cells (LEC) and blood endothelial cells (BEC) were recently established and characterized (18, 21) . Authentication of the lines was performed by short-tandem repeat analyses, parallel to in vitro studies. Determination of cell proliferation and cell death followed earlier descriptions (5).
Abbreviations: BEC, blood endothelial cells; CCID, circular chemorepellent-induced defects; FGF, fibroblast growth factor; FGFR, fibroblast growth factor receptor; HCC, hepatocellular carcinoma; kdFGFR4, dominant-negative fibroblast growth factor receptor 4; LEC, lymphendothelial cells; SCID, severe combined immunodeficiency; solFGFR4, soluble fibroblast growth factor receptor 4. Adenoviral expression vectors for FGFRs have been described (22) . Plasmids coding for human FGFR4 and solFGR4 were kindly provided by Shereen Ezzat (Ontario Cancer Institute, Canada) (23) . The open reading frame was subcloned into pENTR1A (Invitrogen, Carlsbad, CA) with KpnI/XhoI. To generate a kinase-deficient variant (kdFGFR4), the kinase domain was removed by digestion with BglII/NotI and replaced by the Bg1II/NotI-digested sequence of cyan fluorescent protein. The resulting FGFR4-cyan fluorescent protein chimera and the solFGFR4 were transferred into pAd/CMV/V5-Dest by Gateway recombination (Invitrogen). Virus amplification was done as described, and an adenovirus expressing GFP was used as control (24) . Virus titers were determined with the Adeno-X Rapid Titer Kit (Clontech, Mountain View, CA). Cells were exposed to the constructs at the lowest multiplicity of infection leading to 100% cell infection (titrated by a GFP-adenovirus).
Clonogenicity
Forty-eight hours after transfection, cells were plated in medium containing 10% fetal calf serum. At clone appearance in controls, cells were fixed in acetone/methanol (v 50:50) and stained with 0.01% of crystal violet.
Soft agar assay
Forty-eight hours after transfection, cells were suspended in 20% fetal calf serum-RPMI containing 0.3% agar (Sigma) and were seeded onto 20% fetal calf serum-RPMI with 0.6% agar. Three-four weeks later, the number of colonies (>10 cells) was determined.
Cell adhesion assay
Ninety-six-well plates were coated with type 1 collagen or fibronectin (Sigma, St Louis, MO). Cells were plated at a density of 5 × 10 3 per well. After incubation for 60, 90, or 120 min at 37°C, medium was removed, and wells were washed twice with 1× phosphate-buffered saline to eliminate non-adherent cells. The number of adherent cells was determined by the EZ4U assay (Biomedica, Vienna, Austria).
Circular chemorepellent-induced defects assay
Cells (1 × 10 3 ) were incubated in 150 µl EGM2-MV medium (Lonza, Walkersville, MD) containing 20% methylcellulose (M-0512, Sigma) in round bottom microtitre plates (BD-Biosciences) to allow spheroid formation within 48 h. Spheroids were washed in phosphatebuffered saline and transferred to confluent LEC/BEC monolayers, kept in EGM2-MV medium and stained by cytotracker green (2 µg/ ml for 1 h, Invitrogen); four hours later, the spheroid and the circular chemorepellent-induced defects (CCID) area in the LEC/BEC monolayer underneath were photographed. For each condition, the size of ≥10 spheroids and appendant CCIDs was measured by Image-Jsoftware. For details, see Supplementary Figures 1 and 2 , available at Carcinogenesis Online.
Gene expression analyses
For quantitative Real-Time PCR (qRT-PCR), the extracted RNA was processed and measured by the ABI-Prism/7500 Sequence Detection System (Applied-Biosystems, Foster City, CA) using TaqMan-based assays (Applied-Biosystems), as described (5).
For whole-genome expression analyses, the extracted RNA was subjected to quality control (2100 Bioanalyzer-System, Agilent, St Clara, CA) and prepared by 'Low RNA Input Linear Amplification Kit Plus', the 'RNA Spike-In Kit' and the 'Gene Expression Hybridization Kit' according to the manufacturer´s instructions (Agilent). The 4×44k microarray (Agilent) was used as a two color array and was analysed by the G2505B-Microarray-Scanner (Agilent). Samples were analysed in triplicate in each individual experiment. Per run, data were processed by a combination of 'Feature Extraction Software' and 'GeneSpring-GX' (Agilent). Fold-change cutoffs (≥2/≤0.5) were used to select upregulated and downregulated genes, respectively. Differential gene expression was detected by t-test and BenjaminiHochberg correction for multiple testing to ensure a false discovery rate <0.05. The functional annotation analysis on the selected lists was carried out using (i) gene set enrichment analysis to identify significantly enriched curated gene sets (version 3.0) among those included in the MSigDB database (http://www.broadinstitute.org/gsea/msigdb/ index.jsp) and (ii) Ingenuity Pathway Analysis (IPA, version 8.8; Ingenuity Systems, Redwood City, CA; www.ingenuity.com) (25) . For further details, see Supplementary Tables 5 and 6 , available at Carcinogenesis Online.
Immunoblotting
Protein purification, separation and detection followed published protocols (5, 18) . Antibodies used: anti-VSV tag (eBioscience, San Diego, CA); anti-FGFR4 (sc-124 and sc-9006; Santa-Cruz, CA), anti-β-actin (Sigma, St Louis, MO), anti-phospho-PLCγ1(Tyr783) (Cell Signaling, Danvers, MA), anti-PLCγ1 (Cell Signaling), anti-phospho-p44/42 mitogen-activated protein kinase (ERK 1/2) (Thr202/ Tyr204) (Cell Signaling), anti-ERK1/2 (Sigma), anti-phospho-AKT (Ser437) (Cell Signaling), anti-AKT (Cell Signaling). Band intensities were quantified by densitometry (ImageQuant 5.0-software; GE-Healthcare).
Animal study
Cells (1 ×10 6 ) were injected subcutaneously into both flanks of SCID/ BALBc mice by standard procedures. HCC-1.2, HCC-3, and HepG 2 cells were applied in serum-free medium containing 50% matrigel (Becton-Dickinson). The number and diameter of palpable tumours were determined thrice a week. When the local tumour affected the status of the host, the animal was killed for necropsy. The experiments were performed according to the Austrian guidelines for animal care and protection.
Results

Upregulation of FGFR4 enhances the aggressive phenotype of hepatocarcinoma cells
We recently found upregulation of FGFR4 in a subset of HCC (5). We therefore asked whether FGFR4 expression levels affect growth and aggressive phenotype of malignant hepatocytes. The hepatoma/hepatocarcinoma cell lines used differ greatly in clonogenicity, anchorage-dependency in vitro and tumourigenicity in vivo. Thus, CCl-13 cells are highly clonogenic in two different assays and tumourigenic in SCID mice, while HCC-1.2 cells are (almost) incapable of forming clones and tumours. HCC-3 and HepG 2 cells rank in between these two extremes ( Figure 1 ). Spheroids of these hepatoma/hepatocarcinoma cells, attached to LEC or BEC monolayers, were used to simulate a critical step of metastasis, i.e. the gaps/CCID formed in the monolayer mimic entry gates for intravasating tumour emboli. The cell lines also vary in their capacity to disintegrate these lymph-/ blood-endothelial barriers and to form CCID, with CCl-13 being most aggressive in this respect and HCC-1.2 forming only moderate CCID in LEC/BEC monolayers (Figure 1D-F; Supplementary Figures 1 and  2 , available at Carcinogenesis Online).
We generated HCC-1.2 clones with stable overexpression of FGFR4 (Cl1-Cl4). The resulting cells showed considerably elevated levels of FGFR4 mRNA and protein and enhanced levels of phosphorylated ERK and phosphorylated phospholipase-Cγ1 (PLCG1), which indicates activation of the major FGFR-mediated pathways under our experimental conditions (Supplementary Figure 3 , available at Carcinogenesis Online) (8) . When analysing the transcriptome profiles of clones 1 and 3, we found significant, ≥2-fold downregulations of 1295 and ≥2-fold upregulations of 1119 genes (Supplementary Table 2 , available at Carcinogenesis Online). Analyses by 'Gene Set Enrichment' or 'Ingenuity Systems' showed that many of the deregulated genes are involved in bile acid-and phase I and II metabolism as well as in lipid and carbohydrate metabolism, confirming that our cells show known, hepatocyte-specific reaction patterns towards FGFR4-mediated signalling (Supplementary Tables 5 and 6 , available at Carcinogenesis Online) (11, 12) . Furthermore, many deregulations affected pathways being directly or indirectly involved in PLCG-and mitogen-activated protein kinase-mediated signalling. Similar alterations in the expression level of critical genes became evident in human HCC samples with high FGFR4 expression, providing evidence that the hepatocarcinoma cells used are a relevant tool to study FGFR4-driven alterations in hepatocarcinogenesis (Supplementary Table 7 , available at Carcinogenesis Online).
In contrast to vector controls, FGFR4-overexpressing cells became capable to form tumours in SCID mice ( Figure 2C ). Studies on the mechanisms confering tumourigenicity to HCC-1.2 cells revealed that FGFR4 upregulation had little effect on viability, cell cycle or apoptotic activity of the cells (data not shown), but dramatically enhanced the clone-forming capacity of the cells at low density (Figure 2A) . Transcriptome analysis showed that many of the affected genes are involved in cell adhesion, e.g. several members of the collagen, integrin, laminin, lectin, cadherin or protocadherin family were found to be deregulated (Table I ). In line with this observation, adherence of most of the clones to polystyrene, collagen and to some extent also to fibronectin was significantly reduced and growth in soft agar was greatly increased ( Figure 2B and E). We also found upregulation of genes involved in metastasis (Supplementary Tables 2 and 5 , available at Carcinogenesis Online). Accordingly, the capacity of clones to induce CCID in BEC monolayers was greatly increased ( Figure 2D ). This may indicate that overexpressed FGFR4 confers the ability for anchorage-independent growth and for invasiveness into blood-/lymph-endothelium, one of the hallmarks of a malignant cell phenotype.
Knockdown of FGFR4 reduces clone-forming capacity of hepatocarcinoma cell lines
Next, we downmodulated the expression of FGFR4 by siRNA, which significantly reduced mRNA and protein levels in the cells investigated ( Figure 3A and 3B). Viability ( Figure 3C ) as well as cell cycle and apoptotic activity of the cells (data not shown) were not altered, but the formation of clones at low density and in soft agar was significantly reduced (Figure 3D and E). Scrambled siRNA did not impact on any of the test end points (data not shown). These results provide further evidence that endogenous FGFR4 is essential for the protumourigenic phenotype of hepatocarcinoma cells.
Blockade of FGFR4-induced signalling antagonizes tumour formation
To further study the relevance of FGFR4 in malignant transformation, we interfered with FGFR4-mediated signalling. Cells were infected with adenoviral constructs coding for (i) dominant-negative FGFR4, in which the kinase domain had been replaced by cyan fluorescent protein (kdFGFR4) or (ii) the soluble part of FGFR4 (solFGFR4), which is also considered to act dominant negatively by interfering with receptor-ligand interactions (23) . This resulted in high expression of the constructs at the protein level and lowered phosphorylation of the FGFR binding adaptor protein FRS2α (Supplementary  Figures 4 and 5) . Impaired FGFR4 signalling resulted in dramatic reduction of clonogenicity and anchorage-independent growth in all four cell lines ( Figure 4A and B) and lowered the cells' capacity to induce gaps in LEC/BEC monolayers ( Figure 4G ). Correspondingly, tumour-forming capacity tested with the two most tumourigenic lines, HepG 2 and CCl-13, was significantly attenuated ( Figure 4C ). These findings suggest that blockade of FGFR4-mediated signalling is a promising approach to antagonize tumour formation by hepatoma/ hepatocarcinoma cells.
Blockade of FGFR4-mediated signalling may affect late stages of cell proliferation
Studies on the mechanisms underlying the reduced tumourigenicity of cell lines revealed that solFGFR4, and more strongly kdFGFR4, reduced the viability of the cells and increased the apoptotic activity ( Figure 4D and E). Coincidently, a considerable percentage of cells was shifted from the S to the G 0 /G 1 and G 2 /M phase of the cell cycle ( Figure 4F ). Transcriptome profiles revealed that FGFR4 blockade affected mostly genes involved in the formation and/or function of the spindle apparatus or kinetochore complex, as outlined in detail in the Discussion (Table I, Supplementary  Tables 3 and 4 , available at Carcinogenesis Online). Furthermore, the transcripts of genes, which are involved in the initiation and propagation of DNA replication (e.g. CDC7, NOL8) were reduced, while negative regulators of cell cycle (e.g. C13ORF15) tended to be expressed at an enhanced level. Many of these alterations occurred in both, kdFGFR4 or solFGFR4-transfected cells, indicating a similar consequence being more or less independent of the mode of FGFR4 blockade.
To conclude, these findings strongly suggest that expression and function of FGFR4 is an important determinant of the aggressive phenotype of the hepatoma/hepatocarcinoma cell lines tested.
Discussion
Here we show that FGFR4 appears to be a key driver of the aggressive phenotype of hepatoma/hepatocarcinoma cells, as outlined in the following.
For our mechanistic studies, we chose a panel of cell lines, e.g. in barely aggressive HCC-1.2 cells, upregulated FGFR4 expression considerably elevated clone formation, anchorage-independent and Genes involved in the function of: . In (C) cell viability was determined by the EZ4U assay (see Experimental Procedures). In (D), cells were allowed to grow for up to 48 h after transfection, were reseeded and cultivated until the formation of colonies. For further details, see Figure 1 . In (E), 48 h after transfection cells were replated in soft agar and were cultivated until the appearance of colonies. Further details are given in Figure 1 . Abbreviation: n.d., not determined. Data in (A-E) are means ± SD of fold siSCR of three independent experiments. Statistical analyses were performed with the t-test for siFGFR4 versus siSCR: a) P < 0.05; b) P < 0.01; c) P < 0.001; d) P < 0.0001.
Aggressive phenotype of hepatocellular carcinoma
invasive growth and tumourigenicity. For proof of principle, we chose the opposite approach and interfered in aggressive hepatoma/hepatocarcinoma cells with FGFR4 by (i) siRNA-mediated knockdown, (ii) kinase-dead kdFGFR4 for non-functional dimers with endogenous FGFR4 and (iii) solFGFR4 which consists of the IgI-loop/acidic box, lacks ligand-binding domains and nevertheless neutralizes the mitogenic effects of FGFR4 ligands (23) . The IgI-IgII linker region of FGFR1-3 serves as hinge, allowing the IgI-loop/acidic box to autoinhibit the ligand-binding domain (26) . Because FGFR4 harbours the shortest IgI-IgII linker, solFGFR4 may compensate for this lack and compete with FGFs for binding (23, 27) . Here, solFGFR4 lowered phosphorylated FRS2α and altered the expression profiles to a similar extent as kdFGFR4 (Table 1 and Supplementary Figure 5 , available at Carcinogenesis Online). When compared with siRNA, solFGFR4 and kdFGFR4 caused more pronounced effects. The dominant-negative constructs decreased viability, anchorage-independent and invasive growth and tumour formation in vivo. Thus, our data provide strong evidence that up-or downregulation of FGFR4 increases or decreases the aggressive phenotype of malignant hepatocytes, respectively. Furthermore, soluble FGFR4-protein appears as a very promising approach in the therapy of HCC, similar to FP-1039, a soluble decoy FGFR1c receptor being currently applied in a phase-1 clinical trial to treat solid tumours (19; http://www.fiveprime.com/ pipeline/fp-1039). An important hallmark of aggressive tumour cells is their capability to intravasate into the blood or lymphatic vasculature and to extravasate for metastasis formation. Because hepatocarcinoma cells preferably metastasize within the liver, which is hard to simulate in vivo, we established a three-dimensional coculture model of hepatoma/hepatocarcinoma cells with LEC/BEC-monolayers. LEC or BEC retracted and generated CCID, which resembles entry gates for tumour emboli through the lymphatic/blood cell wall. CCID formation could be impaired by inhibitors of I κBα phosphorylation, matrix-metalloproteases and lipoxygenases 12/15-1 (Supplementary Table 1 , available at Carcinogenesis Online). Thus, the activity of NF-κB and secretion of metalloproteases and 12/15-HETE appear to be critical for the disintegration of the lymph/hemangioendothelial barrier by hepatoma/hepatocarcinoma cells, as reported for MCF-7 cells (20) . The CCID formation could be greatly enhanced by overexpressing FGFR4 and impaired by interfering with FGFR4-mediated signalling. Transcriptome analyses revealed upregulation of NFkB-dependent genes by FGFR4 overexpression, such as phospholipase A2, which releases arachidonic acid from the membranes to provide substrate for lipoxygenases-12/15-1 (Supplementary Table 2 , available at Carcinogenesis Online).
The aggressive phenotype is also characterized by altered cell-cell and cell-matrix interactions to enable evasion from organized tissue structures. The increased cloning efficacy of cells overexpressing FGFR4 may indicate a reduced dependency on cell-cell contacts, while the reduced matrix adhesion and the enhanced growth in soft agar reflect lower requirements on anchorage for survival and proliferation.
In contrast to FGFR1-3 and mutant FGFR4, wild-type FGFR4 seems not to interact with neural cell adhesion molecule (28) (29) (30) . Upregulated FGFR4 reduced the expression of several cadherins, protocadherins and integrins, which serve as docking sites for collagens, vitronectin and/or thrombospondins (31, 32) . Furthermore, transcripts encoding for several collagens, vitronectin and thrombospondins were lowered as well (Table I ). These alterations altogether may explain the reduced adhesion of FGFR4-overexpressing hepatocarcinoma cells to collagen, fibronectin and polystyrene.
It is becoming increasingly evident that cell-matrix interactions impact profoundly on several steps of cell division (33) . At start of mitosis, cells loose attachments, disassemble focal adhesions and adopt a round morphology. Cell-adhesion molecules, like β-integrins, regulate centrosome function, spindle formation and orientation, and cytokinesis (34) (35) (36) . In line with these findings is our observation that dominant-negative FGFR4 constructs reduced the proportion of hepatoma/hepatocarcinoma cells in S-phase of the cell cycle and increased the proportion in G 2 /M. This was accompanied by changed transcription of genes involved in the formation and/or function of cohesins, chromosomal condensation, kinetochores, centrosome separation, the formation, stabilization and function of the spindles, and cytokinesis. Furthermore, impaired FGFR4-activity increased anchorage dependency, induced apoptosis and impaired disintegration of the LEC/BEC barrier. On the other hand, overexpressed FGFR4 reduced anchorage dependency and cell adhesion, facilitated proliferation and probably mitosis in the emerging clones and also indirectly affected the interaction with LEC/BEC. Thus, disruption of FGFR4-mediated signalling seems to interfere with mechanisms linking cell-matrix interactions with late stages of cell division and to impact on several important components of the malignant phenotype of hepatoma/ hepatocarcinoma cells.
To conclude, our mechanistic studies demonstrate the oncogenic impact of FGFR4 on the aggressive behaviour of HCC cells. Thus, a great potential might lie in FGFR4 as a target for the treatment of this cancer entity and in the application of solFGFR4-protein as therapeutic tool.
Supplementary material
Supplementary Tables 1-7 and Figures 1-5 can be found at http:// carcin.oxfordjournals.org/
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